Increasing unusual option volume: ISEE AVCT SGFY HEAR TECS CS ING HNST
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
Stifel Reiterates Buy Rating on Iveric Bio (ISEE) as Zimura 'Checks All Efficacy AND Safety Boxes'
September 6, 2022 12:14 PM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $28.00 price target on Iveric Bio (NASDAQ: ISEE) following the release of GATHER-2 (G2) Zimura data that hit high statistical significance on its primary endpoint of mean rate of GA growth (slope) for both square root transformation and... More
Iveric Bio (ISEE) PT Raised to $30 at Cowen; Zimura Has Solid Profile in Likely $4B+ Market
September 6, 2022 11:16 AM EDTCowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $30.00 (from $25.00) while maintaining a Outperform rating following Zimura results, saying it has a solid profile in likely $4B+ market.
The analyst commented, "Iveric bio disclosed positive results from Zimura's... More
Iveric Bio (ISEE) PT Raised to $27 at Credit Suisse
September 6, 2022 10:33 AM EDTCredit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $27.00 (from $24.00) while maintaining a Outperform rating.
The analyst comments "Competitive Dynamic Nuanced, but Valuation Gap Still Favors ISEE Shares. We expect the debate to now shift to... More



